## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.9% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($10.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Viatris shareholders elect directors and approve proposals at annual meeting**
- Source: Investing.com India | 20251205T214529 | Neutral | Relevance: 100%
- Viatris Inc. shareholders have elected thirteen director nominees, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025. These decisions were made at the company's 2025 annual meeting, as reported in an SEC filing and press release. Separately, Viatris also announced strong Q3 2025 earnings, surpassing analyst expectations for both EPS and revenue, though the stock experienced a decline due to other market factors.

**2. BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor**
- Source: markets.businessinsider.com | 20251205T050924 | Neutral | Relevance: 56%
- BioAge Labs announced positive interim Phase 1 data for BGE-102, a brain-penetrant NLRP3 inhibitor, showing it was well-tolerated and achieved significant target engagement with high brain penetration. The study data supports once-daily oral dosing and demonstrates strong suppression of IL-1Î², a key inflammatory cytokine. BioAge is expanding the Phase 1 trial to include participants with obesity and elevated hsCRP, with further data expected in the first half of 2026, aiming for a Phase 2a study initiation.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Volume divergence: price rising (+0.0% MRS) on declining volume (63% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.07 indicates undervaluation relative to growth. Forward P/E 4.4x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.07 |
| Forward P/E | 4.4 |
| Current P/E | 4.7 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.9% (minimal 5-day change). Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.92% (CS: 62) | Neutral |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.154x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $10.93
- **Stop Loss:** $10.39 (4.9% risk)
- **Target:** $11.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 925
- **Position Value:** $10,110.25
- **Portfolio %:** 10.11%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*